Recently, Illumina, the head manufacturer of global gene sequencing instruments, announced that it would lower its performance guidance for 2023 and was lower than market expectations
.
The company expects revenue to reach $4.
99 billion to $5.
03 billion this year, up 7% to 10% year-over-year, below the consensus expectation of about
11% year-over-year growth.
Illumina expects its non-GAAP operating margin to remain around 8% and adjusted earnings per share of $1.
25 to $1.
50 in 2023, also below the consensus expectation of $3.
10
.
Affected by the news, Illumina's shares fell 13.
49%
premarket on Tuesday.
According to the data, Illumina, Inc.
develops, manufactures and sells life science tools and integrated systems for large-scale genetic variation and functional analysis to serve customers in the research, clinical and applied markets, and employs a variety of genomic solutions
.
The company was founded in April 1998 by David R.
Walt, John R.
Stuelpnagel, Anthony W.
Czarnik, Lawrence A.
Bock and Mark S.
Chee and is headquartered in San Diego
, California.
In the domestic gene sequencing market, Illumina used to occupy a huge market share, almost monopolizing the entire market
.
In recent years, with the domestic opportunities brought by the domestic substitution policy, many local enterprises have continued to increase investment in R&D, including BGI, Berry Genomics, and Maijing Genetics, etc.
have emerged in the gene sequencing track, actively "grabbing" the market cake, and are expected to embrace overseas market opportunities
with their rising strength.
Among them, BGI has been listed on the Growth Enterprise Market, the market value once exceeded 100 billion, its subsidiary BGI Intelligent Manufacturing since its establishment in 2016, through technological innovation and product iteration, in the field of gene sequencers has achieved mass production of clinical-grade sequencers, its product layout and performance advantages can be benchmarked against Illumina's products, and has more advantages in cost, performance shows a strong growth momentum; Berry Gene successfully landed on the Shenzhen Stock Exchange with backdoor "Tianxing Instrument" and harvested eight consecutive limit boards
.
However, affected by the epidemic and other factors, the performance of domestic enterprises has also shrunk
.
For example, BGI's third quarter report in 2022 shows that the revenue in the first three quarters was 4.
514 billion yuan, down 12.
38% year-on-year; Achieved a net profit of 747 million yuan, down 47.
16% year-on-year, the company's revenue has declined for six consecutive quarters, and the revenue of 1.
353 billion yuan in the third quarter of 2022 is only half
of the scale in 2020.
According to the third quarter report of Berry Gene in 2022, the company's main revenue was 1.
053 billion yuan, down 5.
32% year-on-year; Net profit attributable to the parent -16.
1942 million yuan, down 157.
74% year-on-year, but in the third quarter of 2022, although the company's main revenue in a single quarter decreased by 1.
54% year-on-year, the net profit attributable to the parent was 2.
4207 million yuan, up 175.
95%
year-on-year.
The industry believes that in the medium and long term, with the downstream market demand-driven, the scale of the gene sequencing market will continue to grow
.
Everbright Securities recently mentioned that according to the development experience of the US sequencing market, the expansion of downstream application scenarios will significantly drive the demand
for upstream sequencers.
In many areas downstream of sequencing, the customer penetration rate in the field of reproductive health is increasing, tumor companion diagnosis is maturing, the tumor early screening market is poised to develop, and the development of new fields such as pathogenic microbial detection is hot, coupled with the demand of the scientific research market, it is expected to drive the demand for upstream sequencers in the medium term
.
According to BCC Research data, the global gene sequencing market has rapidly increased from $2.
4 billion in 2010 to $15.
7 billion in 2021, with a compound growth rate of more than 20%, and is expected to grow at a CAGR of 19.
1% to $37.
721 billion
in 2026.
In China, according to Markets and Markets' forecast, the size of China's sequencer market will reach 30.
4 billion yuan in 2030, and the compound growth rate will be as high as 19.
7%
from 2019 to 2030.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
